Teva Earnings Call Highlights Innovative-Driven Margin Upswing

Teva Pharmaceutical Industries Limited ((TEVA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Teva Pharmaceutical’s latest earnings call struck a confident tone, with management emphasizing solid underlying growth, surging sales in its innovative drugs and continued progress in its multiyear transformation. While near-term headwinds around generics, Emalex accounting and reinvestment will weigh on reported figures, executives argued that the company’s long-term earnings power is improving.

Solid Revenue Base Masked by REVLIMID Headwind

Teva reported about $4.0 billion in Q1 2026 revenue, down roughly 1% in local currency versus a strong prior-year quarter. Adjusting for the Japan divestment and the loss of generic REVLIMID, management said underlying like-for-like revenue grew about 7%, underscoring that the core business is expanding despite tough comparisons.

Innovative Portfolio Becomes a Real Growth Engine

The star of the quarter was the innovative medicines franchise, led by AUSTEDO, UZEDY and AJOVY. AUSTEDO U.S. revenue climbed 41% to $559 million, UZEDY jumped 62% to $63 million, and AJOVY grew 35% to $196 million, lifting innovative products to more than 20% of company revenue, up from about 9% in 2022.

Margins Beat and Long-Term Expansion Path

Non-GAAP gross margin reached 52.9% in Q1, above management’s internal expectations and reinforcing the benefits of mix shift toward higher-margin drugs. Teva reiterated its view that non-GAAP gross margin should land between 54.5% and 55.5% in 2026 and climb above 60% by 2030 as innovative therapies take a larger share.

Profitability and Cash Generation Trend Upward

Adjusted EBITDA came in around $1.1 billion, up about 2% year over year, while non-GAAP EPS ticked up to $0.53 from $0.52 despite reinvestment. Free cash flow improved sharply to roughly $188 million versus $107 million a year ago, a roughly 76% increase that supports ongoing deleveraging and selective deal-making.

Leverage Declines, Path to Investment-Grade Narrows

Teva continued to chip away at its debt load, bringing net debt to EBITDA down to about 2.42 times by quarter-end. Management reiterated its goal of cutting leverage below 2.0 times by 2027 and highlighted that the improving balance sheet is a key pillar in its push toward an investment-grade credit profile.

Transformation Savings On Schedule

The company’s Pivot to Growth program is targeting $700 million of savings by 2027, and management said execution is tracking to plan. Teva expects about two-thirds of those savings to be realized by the end of 2026, with restructuring charges and cash outflows, including roughly $205 million booked in 2025 and an additional $25 million in Q1 2026, in line with earlier plans.

Emalex Deal Targets High-Margin Tourette Opportunity

Teva announced a deal to acquire Emalex for $700 million upfront plus up to $200 million in milestones, centered on ecopipam for Tourette syndrome. The company expects ecopipam, described as first-in-class, to carry an attractive gross margin profile of around 80%, with regulatory filing planned for the second half of 2026 and initial launch contribution from 2027 and EPS accretion from 2028.

Biosimilars and Higher-Value Generics Build Scale

Management highlighted continued expansion in biosimilars, where Teva now has 11 products on the market. The pipeline includes four more biosimilars through 2027 covering about $16 billion in originator sales and a further nine targeting roughly $58 billion thereafter, positioning the company for growing contributions from higher-value generics and complex products.

R&D Pipeline Offers Multibillion-Dollar Upside

Teva pointed to a busy year of R&D milestones across neurology, immunology and other areas, with seven key clinical readouts expected, including duvakitug maintenance data, anti–IL-15 in vitiligo and celiac disease, DARI Phase III progress, an emrusolmin futility look and PD-1–IL-2 data. Management estimates the overall pipeline could support more than $10 billion in potential peak sales if successful.

Generics Hit by REVLIMID, Underlying U.S. Growth

Global generics revenue fell about 13% year over year in Q1, mainly because last year’s quarter included around $300 million from generic REVLIMID. Reported U.S. generics revenue dropped about 28%, but excluding REVLIMID, U.S. generics actually grew roughly 10%, highlighting how the loss of a single large product distorts the headline decline.

Emalex Accounting to Depress 2026 Reported Earnings

Because the Emalex transaction is structured as an asset purchase, the $700 million upfront payment will run through R&D expense in 2026 rather than being capitalized. Management also expects about $75 million in additional operating costs starting in the third quarter of 2026, implying roughly $775 million of pressure on 2026 reported operating profit, EBITDA and EPS despite the deal’s strategic appeal.

Operating Margins Reflect Heavy Reinvestment

Non-GAAP operating margin slipped about 50 basis points year over year to roughly 24% in Q1 as Teva stepped up sales and marketing to fuel AUSTEDO, UZEDY and AJOVY. Executives emphasized that this is a deliberate trade-off and that, even with near-term pressure from reinvestment and deal costs, they still aim to reach a 30% non-GAAP operating margin by 2027.

Channel Timing and AUSTEDO Destocking Unclear

Management flagged that expected channel inventory drawdowns did not fully materialize in the quarter, affecting the timing of revenue recognition through the rest of 2026. They also cautioned that AUSTEDO dynamics could be choppy ahead of expected pricing changes in early 2027, which may drive additional channel adjustments in late 2026.

Restructuring Cash Flows Weigh Near Term

Teva reminded investors that ongoing transformation efforts bring short-term cash outflows even as they support long-term efficiency. The company cited about $205 million of restructuring charges in 2025 with roughly $100 million in cash outflows, plus an extra $25 million in Q1 2026 and anticipated full-year 2026 cash outflows of $90 million to $100 million tied to the program.

Pipeline Execution and Generics Volatility Still Key Risks

Management acknowledged that several upcoming clinical milestones, including an emrusolmin futility analysis, carry binary risk that could significantly influence future revenue. They also noted that generics trends remain lumpy and competitive, with seasonal effects in Europe, launch timing and product-specific factors driving volatility in quarterly results despite the broader strategic shift.

Guidance Reaffirmed Amid Emalex Impact

Teva reaffirmed its 2026 outlook on an underlying basis, still calling for mid–single-digit revenue growth, improving EBITDA and non-GAAP gross margin of 54.5% to 55.5%, alongside operating expenses at 27% to 28% of sales and free cash flow between $2.0 billion and $2.4 billion. Longer term, the company maintained 2027 targets for a 30% non-GAAP operating margin, net debt to EBITDA below 2.0 times and cash conversion of about 80%, even after incorporating the Emalex accounting hit.

Teva’s latest earnings call painted a picture of a company steadily reshaping itself around higher-margin innovative drugs while tightening its balance sheet. Investors will need to look past short-term noise from generics, restructuring and Emalex-related accounting, but the improving growth mix, margin trajectory and clear capital allocation framework suggest a more durable earnings profile is taking shape.